The DSMB recommendation was to not unblind the dat

The DSMB recommendation was to not unblind the data. I think NP is wise to follow that recommendation. One of the best questions of the CC was has the FDA seen the interim analysis data? We can complain all we want about the FDA being corrupt (which I believe they are) but they have not even seen our severe critical data. From the start of the trial NP has chosen to not apply for government funding or assistance. I think his strategy is once the FDA sees the positive trial data they will follow with an EUA and all the help we need on funding, manufacturing & distributing. It makes you wonder if we are on the FDA's radar at all. We need to fill the trial asap and pray that the next interim analysis haults the trial because doing interim analysis slows down enrollment bigtime. The remdesivir approval is beyond frustrating. One positive way to look at it is we all agree we can show better results than placebo or remdesivir so this is a good opportunity for Leronlimab to show what its got!